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Diagnosis
IFN-gamma
AntigensIFN-γ release assays (IGRAs) are better indicators ofMycobacterium tuberculosis infection than the tuberculin skin
test (TST) in Bacillus Calmette–Guérin (BCG)-vaccinated populations. However, IGRAs do not discriminate active
and latent infections (LTBI) and no gold standard for LTBI diagnosis is available. Thus, since improved tests to di-
agnoseM. tuberculosis infection are required, we assessed the efﬁcacy of severalM. tuberculosis latency antigens.
BCG-vaccinated healthy donors (HD) and tuberculosis (TB) patients were recruited. QuantiFERON-TB Gold
In-Tube, TST and clinical data were used to differentiate LTBI. IFN-γ production against CFP-10, ESAT-6,
Rv2624c, Rv2626c and Rv2628 antigenswas tested in peripheral bloodmononuclear cells. LTBI subjects secreted
signiﬁcantly higher IFN-γ levels against Rv2626c than HD. Additionally, Rv2626c peptide pools to which only
LTBI responded were identiﬁed, and their cumulative IFN-γ response improved LTBI discrimination. Interesting-
ly, whole blood stimulation with Rv2626c allowed the discrimination between active and latent infections, since
TB patients did not secrete IFN-γ against Rv2626c, in contrast to CFP-10+ESAT-6 stimulation that induced IFN-γ
response from both LTBI and TB patients. ROC analysis conﬁrmed that Rv2626c discriminated LTBI from HD and
TBpatients. Therefore, since only LTBI recognizes speciﬁc epitopes fromRv2626c, this antigen could improve LTBI
diagnosis, even in BCG-vaccinated people.
© 2015 The Authors. Published by Elsevier B.V. This is an open access article under the CC BY-NC-ND license
(http://creativecommons.org/licenses/by-nc-nd/4.0/).1. Introduction
Tuberculosis (TB) continues to be one of the most prevalent infec-
tious diseases worldwide, with 9 million new cases reported and 1.5
million deaths in 2013 (W.H.O., 2014). Furthermore, an estimated one
third of the world population is latently infected with Mycobacterium
tuberculosis (LTBI) and at risk of disease reactivation (Dye et al., 1999).
The existence of such a huge reservoir of the bacteria denotes theiológica — IQUIBICEN, Facultad
ires, Intendente Güiraldes 2160,
EGA Buenos Aires, Argentina.
. This is an open access article underneed of a rapid diagnosis of TB infection for its early detection and
control.
The tuberculin skin test (TST) has been long the most used tool for
the diagnosis of M. tuberculosis infection (Vukmanovic-Stejic et al.,
2006). However, TST speciﬁcity is limited since it employs antigens
shared with environmental mycobacteria and Mycobacterium bovis
Bacillus Calmette–Guérin (BCG) (Shingadia and Novelli, 2008). Further-
more, TST cannot differentiate active disease from LTBI, requiring addi-
tional tests to establish the diagnosis. The discovery of the diagnostic
potential of the M. tuberculosis antigens ESAT-6 and CFP-10 led to the
development of IFN-γ release assays (IGRAs) (Diel et al., 2011). These
antigens are encoded in the region of deletion-1 locus present in
M. tuberculosis, but absent in BCG and most environmental myco-
bacteria, making IGRAs more speciﬁc than TST (Diel et al., 2011;the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
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TST, they do not discriminate active from latent infection, a key problem
in cases with uncertain clinical symptoms or smear negative sputum
samples, like extra-pulmonary TB cases (Chegou et al., 2011). Though
this is not themain objective of IGRAs, such discriminationwould bede-
sired, since it would bring greater speciﬁcity to the assay, providing an
extra tool for fast diagnosis of active infection. In addition, there is as
yet no gold standard for the diagnosis of LTBI. Besides, several vaccine
studies are being currently performed employing antigens present in
existing IGRAs, with many having demonstrated the potential of
ESAT-6 to confer protection againstM. tuberculosis (Davila et al., 2012;
Cervantes-Villagrana et al., 2013; Reither et al., 2014; van Dissel et al.,
2011). Therefore, if these vaccines prove to be successful and become
commonly used, itmight signify the end of ESAT-6 as a diagnosticmark-
er, since immune response to this antigen would reﬂect both
M. tuberculosis infection and vaccination, losing its present speciﬁcity.
Finally, the performance of available IGRAs exhibits great variability
amongdifferent groups of immunocompromised patients, being depen-
dent upon the nature and extent of immunodeﬁciency (Sauzullo et al.,
2015). Thus, the reasons described above support the search for better
assays and/or new immunological biomarkers to diagnose
M. tuberculosis infection, which might complement or improve current
assays to diagnose both latent and active infections.
LTBI is thought to be associated with a dormancy state of the patho-
gen and several antigens up-regulated during these conditions have
been analyzed as potential diagnostic markers (Schuck et al., 2009).
We studied the response of healthy subjects, LTBI individuals and TB pa-
tients to several M. tuberculosis antigens. DosR regulon-encoded anti-
gens Rv2624c, Rv2626c and Rv2628 were selected based on previous
reports that suggested they were recognized by household contacts or
TST+ individuals (Leyten et al., 2006; Chegou et al., 2012). Our results
demonstrated that LTBI individuals recognized speciﬁc epitopes from
Rv2626c that induced the secretion of signiﬁcant amounts of IFN-γ, in
sharp contrast to non-infected individuals. Moreover, our ﬁndings indi-
cate that Rv2626c would be a useful antigen to discriminate LTBI indi-
viduals from both active TB patients and non-infected healthy subjects
in a BCG-vaccinated population. Additional studies will validate the po-
tential of Rv2626c to discriminate LTBI from TB patients and healthy do-
nors in non-BCG-vaccinated populations.
2. Methods
2.1. Study Subjects
BCG-vaccinated healthy adults lacking a history of TB (household
contacts and healthcare workers) were recruited at Argentinean Refer-
ral Hospitals between January 2012 and August 2014. Among this group
of individuals, diagnosis of LTBI was established using QuantiFERON-TB
Gold In-Tube (QFT-GIT; Qiagen, USA; according to the manufacturer's
directions) and TST (see below) tests. LTBI diagnosis was assigned to
any subject with a positive QFT-GIT/TST and no clinical or radiological
evidence of active TB. In the event of discordant QFT-GIT/TST results, in-
dividuals were assigned to the corresponding group on the basis of the
QFT-GIT result. The group of healthy donors (HD) was comprised by
adult individuals without TB disease (tested by chest X-rays and analy-
sis of acid-fast bacilli in sputum) and with negative QFT-GIT/TST.
HIV-uninfected patients with active TB were evaluated at Dr. F. Muñiz
or Dr. E. Tornú Hospitals (Buenos Aires, Argentina). Diagnosis of TB dis-
ease was established based on clinical and radiological data together
with culture-conﬁrmation and the identiﬁcation of acid-fast bacilli in
sputum. Patients included in this study had received less than one
week of anti-TB therapy. Information regarding demographic data and
prior TB exposure was obtained at the time of recruitment. A total of
56 LTBI individuals, 56 TB patients and 60 HD participated in this
study. All participants provided written informed consent for sample
collection and subsequent analysis. The protocols conducted wereapproved by the Ethical Committee of the Dr. F. Muñiz and the
Dr. E. Tornú Hospitals.2.2. Study Inclusion and Exclusion Criteria for Individuals Participating in
the Study
Inclusion criteria: a) adult (over 18 years old) men and women with
active pulmonary TB and b) healthy volunteerswith high level of ex-
posure to M. tuberculosis (household contacts of TB patients and
healthcareworkers of National Referral Hospitals for TB). All recruit-
ed subjects were BCG-vaccinated. QFT-GIT and TST assayswere used
to determine thepresence of LTBI among individualswithout clinical
or microbiological diagnosis of active TB. All TB patients included in
the study had a positive culture forM. tuberculosis.
Exclusion criteria: a) HIV positive or positive serology to other viral or
bacterial infections; b) patients with diabetes, cancer, autoimmune
diseases or other conditions that may affect the immune system of
the individual; c) pregnant women and d) children. Among the
population of active TB patients we excluded: a) patients with
multidrug-resistant tuberculosis (MDR-TB) infection and b) patients
with more than seven consecutive days of anti-TB treatment.
Individuals with indeterminate QFT-GIT results were also excluded
from the study.
2.3. Tuberculin Skin Test (TST)
TST was administered by medical staff according to the Mantoux
method (American Thoracic Society, CDC, 2000). Brieﬂy, 2 tuberculin
units (0.1 ml) of puriﬁed protein derivative (Instituto Malbrán, Buenos
Aires, Argentina) were intradermally injected into the inner surface of
the forearm. The skin induration was measured (in mm) after 48–72 h
by trained personnel at one of the medical centers. A positive TST was
deﬁned as an induration size ≥10mm, according to National Guidelines
(Zerbini, 2013).2.4. Antigens
Recombinant antigens (Rv2624c, Rv2626c, Rv2628, CFP-10, ESAT-6)
were produced in Escherichia coli BL21 (DE3) pLysS and puriﬁed using a
nickel nitrilotriacetic system (Ni-NTA Agarose, Qiagen), following the
manufacturers' directions. After purity control, proteins were concen-
trated using Amicon (Millipore, USA) commercial columns and then
Detoxi-Gel Endotoxin Removing Resin (Pierce, USA) was used to re-
move possible endotoxin traces. CFP-10 and ESAT-6-induced IFN-γ re-
sponses were compared to those elicited with the respective protein
reference standard obtained from BEI Resources (NIAID, NIH; CFP-10
Recombinant Protein Reference Standard, NR-14869 and ESAT-6
Recombinant Protein Reference Standard, NR-14868). Cell lysate from
the virulent M. tuberculosis H37Rv strain (Mtb-Ag) was prepared by
probe sonication (BEI Resources, NIAID, NIH: M. tuberculosis, Strain
H37Rv, Whole Cell Lysate, NR-14822).2.5. Peptides
Overlapping synthetic peptides (13–15-mers, overlapped by 11
amino acids; 36 in total) spanning the sequence of Rv2626c were syn-
thesized by Biomatik Corp. (Canada) using Fmoc chemistry. Peptide pu-
rity was N80%, as assayed by HPLC, and the composition was veriﬁed by
mass spectrometry. Lyophilized peptides were dissolved in dimethyl
sulfoxide, aliquoted and stored at−70 °C. For in vitro stimulation, pep-
tides were arranged in pools composed of six peptides, obtaining six
consecutive pools (A–E) covering the complete Rv2626c sequence.
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Fig. 1. Heat map for IFN-γ responses to Mtb-Ag, Rv2626c, CFP-10 and ESAT-6
M. tuberculosis antigens in subjects without active tuberculosis. Heat map showing the
IFN-γ responses toMtb-Ag, Rv2626c, CFP-10 or ESAT-6 antigens as measured in cell free
supernatants of peripheral bloodmononuclear cells (PBMCs) from subjects without active
tuberculosis (non-TB; n= 20). Colors represent pg/ml of IFN-γ produced in each individ-
ual, where high values are shown in red and low values in light yellow, as shown in the
ﬁgure scale. Right column displays the result of QuantiFERON-TB Gold In-tube (QFT-GIT)
test.
886 D. Peña et al. / EBioMedicine 2 (2015) 884–8902.6. Cell preparation and reagents
Peripheral blood mononuclear cells (PBMCs) were isolated by cen-
trifugation over Ficoll-Hypaque (GE Healthcare, USA) and cultured
(1 × 106 cells/ml) with/without the different M. tuberculosis antigens
(Rv2624c, Rv2626c, Rv2628, CFP-10, ESAT-6; 2.5 μg/ml) or Rv2626c
peptide pools (each peptide at 5 μg/ml) with RPMI 1640 (Gibco, USA)
supplemented with L-glutamine, penicillin/streptomycin and 10%
human serum (Sigma-Aldrich, USA), during different times. Brieﬂy,
PBMCs were stimulated for ﬁve days and then cell free supernatants
were collected to determine the levels of IFN-γ by ELISA (Human
IFN-γ ELISA MAX™ Standard Kit, BioLegend, USA). In different experi-
ments, cells were incubated with the antigens for four days and then
harvested to determine IFN-γ expression by ﬂow cytometry (see
below).
2.7. Whole blood stimulation
Brieﬂy, 0.5 ml of heparinized blood was treated with Rv2626c or
CFP-10 + ESAT-6 (2.5 μg/ml) for 24 h at 37 °C. Afterwards, plates
were centrifuged and plasma was recovered to determine IFN-γ pro-
duction by ELISA.
2.8. Flow cytometry
After four days of PBMCs stimulation, GolgiStop® (BD Biosciences,
USA) reagent was added for the last 5 h of culture. Cells were then har-
vested and stained for intracellular IFN-γ (eBioscience, USA) and sur-
face CD4 (BioLegend) expression using Cytoﬁx/Cytoperm™ ﬁxation/
permeabilization buffers following the manufacturer's instructions
(BD Biosciences) (Supplementary appendix). Negative control samples
were incubated with irrelevant isotype-matched antibodies in parallel
with experimental samples. Samples were analyzed on a FACS ARIA II
ﬂow cytometer (BD Biosciences).
2.9. Statistics
Individuals with a similar pattern of IFN-γ cytokine secretion were
grouped together as clusters and presented as a heat map; with heat
distances computed using Euclidean distances as similarity measure,
employing NetWalker 1.0 software.
The Mann–Whitney test was used to analyze differences between
unpaired samples. Fisher's exact test was used for categorical variables.
Receiver operating characteristic (ROC) curve analysis was conducted
to analyze the predictive value of IFN-γ response to Rv2626c or CFP-
10 + ESAT-6, calculating the area under the curve (AUC) and the 95%
conﬁdence interval (CI). Analyses were performed using GraphPad
Prism 5 software. p b 0.05 was considered statistically signiﬁcant.
3. Results
3.1. Evaluation of IFN-γ Responses to M. tuberculosis Antigens in
BCG-Vaccinated People
To assess the frequency of LTBI individuals among healthy BCG-
vaccinated people highly exposed to M. tuberculosis, we analyzed the
IFN-γ response to several dormancy (Rv2626c, Rv2628, Rv2624c) and
speciﬁc early secretory (ESAT-6, CFP-10) antigens from the pathogen.
Initially, IFN-γ production against the mentioned antigens or Mtb-Ag
was evaluated in PBMCs from 20 healthy individuals. As shown by the
heat map in Fig. 1, all subjects produced elevated amounts of IFN-γ
against Mtb-Ag (N600 pg/ml), as expected in BCG-vaccinated individ-
uals. Interestingly, 7 out of 20 (35%) of the persons tested also
responded simultaneously with high intensity to three antigens:
Rv2626c, ESAT-6 and CFP-10. In fact, the three antigens induced
N600 pg/ml of IFN-γ in 5 out of the 7 subjects. The two exceptionswere one individual in which Rv2626c and ESAT-6 induced
400–600 pg/ml and CFP-10 induced N600 pg/ml of IFN-γ, and another
person in which Rv2626c induced 200–400 pg/ml and CFP-10 and
ESAT-6 induced N600 pg/ml. In contrast to our data resulting from stim-
ulationwith Rv2626c, ESAT-6 and CFP-10 showing that 7 individuals si-
multaneously secreted high levels of IFN-γ to those antigens (all above
200 pg/ml), none of those subjects secreted IFN-γ against Rv2624c, and
only 2 produced levels of IFN-γ above 200 pg/ml in response to Rv2628
stimulation (data not shown). Therefore, Fig. 1 represents the results
obtained with antigens that displayed noticeable differences among
individuals: Rv2626c, ESAT-6 and CFP-10.
We then characterized the healthy population that secreted high
IFN-γ levels to the mentioned three antigens with the QFT-GIT test.
Fig. 1 shows that all the subjects that highly responded to Rv2626c,
ESAT-6 and CFP-10 simultaneously were QFT-GIT+, whichwould be in-
dicative of LTBI; while all those individuals that did not respond were
QFT-GIT−.
In view of the ﬁndings described above, we next investigated the re-
sponse toM. tuberculosis antigens in a larger population of QFT-GIT−HD
and QFT-GIT+ LTBI individuals (Table 1). We also stimulated all sub-
jects' PBMCs simultaneously with the combination of antigens included
in the QFT-GIT assay, i.e.,: CFP-10 + ESAT-6. As shown in Table 2, LTBI
produced signiﬁcantly higher IFN-γ levels against CFP-10, ESAT-6 and
CFP-10+ ESAT-6 than HD. Interestingly, LTBI subjects also secreted sig-
niﬁcantly more elevated IFN-γ levels upon Rv2626c stimulation than
HD (Table 2), suggesting that stimulation with Rv2626c might also be
useful to discriminate between HD and LTBI. To conﬁrm these ﬁndings
Table 1
Characteristics of Individuals without active TB infection.
Characteristics Individuals without active
M. tuberculosis infection
(N = 116) p value
QFT-GIT (−) QFT-GIT (+)
52% (N = 60) 48% (N = 56)
Age (years) 40.5 ± 11.9 42.0 ± 11.6 0.49 (a)
Sex
Male 38% (N = 23) 40% (N = 22) 0.85 (b)
Female 62% (N = 37) 60% (N = 34)
Country of birth
Argentina 88% (N = 53) 80% (N = 45) 0.31 (b)
Other Latin American countries 12% (N = 7) 20% (N = 11)
TST
Positive 14% (N = 8) 78% (N = 44) b0.001 (b)
Negative 86% (N = 52) 22% (N = 12)
Abbreviations: QuantiFERON-TB Gold In-tube, QFT-GIT; tuberculin skin test, TST.
(a) Age values are displayed as Mean ± SEM. p values were calculated by the Mann–
Whitney U test for continuous variables; (b) p values were calculated by Fisher's exact
test for categorical variables.
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(Supplementary Fig. 1). In agreement to the results obtained by ELISA,
PBMCs from LTBI displayed signiﬁcantly higher numbers of IFN-γ se-
creting CD4+ cells in response to Rv2626c as compared to HD (Supple-
mentary Table 1). Regarding the other antigens tested, in both HD and
LTBI, Rv2624c induced a veryweak IFN-γ response (Table 2). Moreover,
although LTBI subjects secreted low IFN-γ levels in response to Rv2628,
theywere not signiﬁcantly different compared to those produced byHD
(Table 2).
In order to evaluate the potential use of Rv2626c in discriminating
LTBI vs. HD, we next performed a ROC analysis for the IFN-γ responses
to this antigen (shown in Table 2), obtaining signiﬁcant results for
AUC analysis (AUC, 0.86; p b 0.001; 95% CI: 0.78–0.93). Together,
these ﬁndings demonstrated that Rv2626c might allow discriminating
LTBI individuals from HD.3.2. Identiﬁcation of Immunodominant Peptide Pools Derived fromRv2626c
Antigen
Since a low percentage of HD showed a weak IFN-γ production
against Rv2626c (Table 2), and an ideal diagnostic test requires the
highest discrimination among groups under study, we next searched
for the immunodominant regions of Rv2626c to which only LTBI
responded. For this, we employed overlapping peptides arranged in
pools composed of six peptides each, covering the entire Rv2626c pro-
tein. As can be observed in Table 3, pools B, D and F induced high
IFN-γ levels, which signiﬁcantly discriminated between LTBI and HD,
while pools C and E also distinguished between both groups but with
a weaker signiﬁcance (Table 3). In contrast, although stimulation with
pool A did induce the production of IFN-γ in LTBI subjects, no signiﬁcant
differences with HD were detected (Table 3). Therefore, pool A would
belong to a less speciﬁc region of Rv2626c than pools B, D and F, theTable 2
IFN-γ production againstM. tuberculosis antigens by PBMCs from non-TB individuals.
pg/ml of IFN-γ, Mean ± SEM (range, pg/ml)
N CFP-10 ESAT-6 CFP
HD 45 250 ± 52.8
(1–1102)
196 ± 43.3
(2–895)
248
(8–
LTBI 56 1452 ± 202.0
(1–4127)
973 ± 156.2
(5–3958)
151
(7–
p value b0.001 b0.001 b0.0
Peripheral bloodmononuclear cells (PBMCs) fromhealthy donors (HD) and latentlyM. tubercul
CFP-10 + ESAT-6, Rv2624c, Rv2626c or Rv2628 (2.5 μg/ml) for ﬁve days. Then, cell free supern
calculated using the Mann–Whitney test for unpaired samples.most speciﬁc and immunogenic ones,which could strongly differentiate
the two groups of individuals.
We next analyzed the difference in the levels of IFN-γ secreted by
LTBI and HD in response to Rv2626c antigen or each of themost speciﬁc
peptide pools. We observed that upon stimulation with Rv2626c, LTBI
subjects showed an eight times greater response than HD (Table 2),
whereas with the pools, the response was 70 (pool B), 23 (pool D) or
15 (pool F) times greater in LTBI than in HD (Table 3), clearly improving
the discrimination between HD and LTBI individuals. Since each LTBI
subject recognized the individual peptide pools with different intensity,
we then calculated the cumulative IFN-γ response to the most speciﬁc
and immunogenic pools (B, D and F) to capture the overall immune re-
sponse to the tested peptide pools for each person. As shown in Table 3,
our results showed a signiﬁcantly higher cumulative IFN-γ response to
these pools in the group of LTBI individuals than in HD. Thus, our ﬁnd-
ings indicate that LTBI individuals recognized epitopes from Rv2626c
antigen and showed a strong cumulative IFN-γ response, in clear con-
trast to HD that display weak or no response to those peptides.
3.3. IFN-γ Responses toM. tuberculosis Speciﬁc Antigens in Healthy Donors,
LTBI Individuals and TB Patients
Since we classiﬁed our population using QFT-GIT assay, and consid-
ering that this test uses whole blood for more practical and faster test-
ing, we also analyzed the response to Rv2626c stimulating whole
blood. Given that both current IGRAs discriminateM. tuberculosis infec-
tion (active or latent) from non-infected individuals, we also examined
the response of active TB patients (Table 4). We ﬁrst investigated the
response of PBMCs from TB patients, LTBI and HD to Rv2626c and
CFP-10 + ESAT-6 (Fig. 2A). We found that, as expected, both active
and latently infected individuals (TB patients and LTBI) secreted signif-
icantly higher IFN-γ amounts in response to CFP-10 + ESAT-6 as com-
pared to HD. Interestingly, we observed that stimulation with Rv2626c
allowed the discrimination between active and latent infections
(Fig. 2A) since TB patients did not secrete IFN-γ against this antigen
(Fig. 2A), in sharp contrast to the results obtained with CFP-
10 + ESAT-6. When we performed our experiments in whole blood,
we obtained similar results to those observed in PBMCs: LTBI subjects
secreted signiﬁcantly higher amounts of IFN-γ in response to Rv2626c
than HD. In addition, like in PBMCs (Fig. 2A), we observed that TB pa-
tients did not produce IFN-γ against Rv2626c (Fig. 2B), in sharp contrast
to the results obtained with CFP-10 + ESAT-6 (Fig. 2B). Furthermore,
the ROC analysis for IFN-γ responses to Rv2626c in whole blood rein-
forced the potential of Rv2626c antigen for discriminating LTBI individ-
uals from non-LTBI individuals (patients with active TB or HD; Fig. 2C;
AUC, 0.86; p b 0.001; 95% CI: 0.78–0.93). Additionally, by using the
data obtained in whole blood and the Youden index (Youden, 1950;
Perkins and Schisterman, 2006), we were able to establish an optimal
cut off point of N63.35 pg/ml of IFN-γ, with 78.26% sensitivity and
89.36% speciﬁcity. For comparison, Fig. 2D also shows the ROC curve ob-
tained after analyzing the IFN-γ response to CFP-10 + ESAT-6 for the
discrimination of M. tuberculosis infected individuals (LTBI + TB pa-
tients) versus HD. In conclusion, our ﬁndings show that the response-10 + ESAT-6 Rv2626c Rv2624c Rv2628
± 76.3
578)
69 ± 24.5
(1–476)
36 ± 13.9
(1–104)
33 ± 14.4
(1–150)
7 ± 210.0
3888)
549 ± 106.6
(14–2892)
39 ± 24.9
(1–169)
135 ± 60.2
(1–461)
01 b0.001 0.84 0.15
osis infected individuals (LTBI) were culturedwithM. tuberculosis antigens CFP-10, ESAT-6,
atants were recovered and the production of IFN-γwas evaluated by ELISA. p values were
Table 3
IFN-γ production against overlapping peptides of Rv2626c by PBMCs from non-TB individuals.
pg/ml of IFN-γ, Mean ± SEM
N Pool A Pool B Pool C Pool D Pool E Pool F Cumulative response to pools B, D and F
HD 33 7.6 ± 4.09 3.9 ± 1.6 4.1 ± 6.0 18.4 ± 18.4 4.9 ± 3.4 34.4 ± 20.0 55.3 ± 20.92
LTBI 40 216.6 ± 82.7 275.9 ± 93.1 119.2 ± 35.7 416.2 ± 120.3 48.7 ± 20.7 517.1 ± 119.3 1177.0 ± 253.1
p value 0.09 b0.001 0.03 b0.001 0.02 b0.001 b0.001
Peripheral blood mononuclear cells (PBMCs) from healthy donors (HD) and latentlyM. tuberculosis infected individuals (LTBI) were cultured with six peptide pools (A–F) derived from
Rv2626c (5 μg/ml of each peptide) for ﬁve days and then IFN-γ productionwas evaluated in cell free supernatants by ELISA. The cumulative response to pools B, D and Fwas calculated for
each individual as the sum of the secretion of IFN-γ in response to each of the three pools. p values were obtained though the Mann–Whitney test for unpaired samples.
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ilar to ESAT-6 and CFP-10, antigens employed in IGRAs like QFT-GIT.
However, in contrast to QFT-GIT assay, stimulation with Rv2626c
would also allow the discrimination between active and latent infec-
tions. Therefore, our results indicate that Rv2626c might be useful not
only to diagnose LTBI, but also, to differentiate latent from active
M. tuberculosis infection.
4. Discussion
Amain health obstacle to control TB is that latent bacilli may remain
viable for decades and reactivate later to cause active TB. Thus, there is a
need to identify LTBI individuals and treat them to eliminate the risk of
developing TB. Since there is no diagnostic gold standard for LTBI and
several reports have demonstrated the potential use of antigens
employed in current IGRAs as protective vaccines, it urges to ﬁnd new
M. tuberculosis antigens to detect latently infected individuals (Davila
et al., 2012; Cervantes-Villagrana et al., 2013; Reither et al., 2014; van
Dissel et al., 2011; Sester et al., 2011).
Currently, both TST and IGRAs are used for LTBI diagnosis world-
wide. Still, in BCG-vaccinated populations IGRAs may be preferable to
TST since they are more speciﬁc forM. tuberculosis infection (Pai et al.,
2014). In fact, in our study 13% of the individuals assessed had discor-
dant results between TST and IGRA tests (Supplementary Fig. 2). To de-
velop T cell-based assays that discriminate active TB and LTBI,
improving the current available tests, it is necessary to identify new
host markers expressed in response to M. tuberculosis antigens that
are uniquely recognized by LTBI individuals (Chegou et al., 2012).Table 4
Characteristics of patients with active TB infection.
Characteristics Tuberculosis patients (TB)
(N = 56)
Age (years) (a) 34.5 ± 13.4
Sex (b)
Male 86% (N = 48)
Female 14% (N = 8)
Country of birth
Argentina 53% (N = 30)
Other Latin American countries 47% (N = 26)
TST
Positive 98% (N = 55)
Negative 2% (N = 1)
AFB in sputum smear
Positive 84% (N = 47)
Negative 16% (N = 9)
Radiological lesions (c)
Severe 80% (N = 45)
Moderate 20% (N = 11)
Mild 0% (N = 0)
(a) Age values are displayed as Mean ± SEM. (b) Categorical data are expressed as per-
centages (number). (c) Radiological lesions: mild, patients with a single lobe involved
and without visible cavities; moderate, patients presenting unilateral involvement of
two or more lobes with cavities, if present, reaching a total diameter no greater than 4
cm; severe, bilateral diseasewithmassive affectation andmultiple cavities. Abbreviations:
AFB, acid-fast bacilli.Thus, present IGRAs might be complemented by using antigens to
which patients with active TB do not respond.
Here, we describe an immune-stimulatory function of the 16-kDa
conserved protein coded by the M. tuberculosis open reading frame
Rv2626c, one of the most abundant proteins under low-oxygen condi-
tions in M. tuberculosis lysates (Rosenkrands et al., 2002). Variable re-
sults using Rv2628 and Rv2626c latency antigens were reported by
others, although the disparities could be related to differences in stimu-
lation schemes, antigen concentrations, ethnic backgrounds, and BCG
vaccination history (Schuck et al., 2009; Chegou et al., 2012; Lin et al.,
2007; Black et al., 2009; Riano et al., 2012; Hozumi et al., 2013;
Mensah et al., 2014). Bashir et al. reported that Rv2626c induced higher
IFN-γ levels in TB patients than in HD, but LTBI individuals were not an-
alyzed in this study (Bashir et al., 2010). Leyten et al. demonstrated that
TST+ individuals strongly recognized more latency antigens (e.g.,:
Rv2628 and Rv2626c) as compared to cured patients or patients under-
going anti-TB treatment (Leyten et al., 2006). The study by Goletti et al.
evaluated T-cell IFN-γ responses toM. tuberculosis latency antigens in a
mainly European population composed by subjects at different stages of
TB infection, concluding that remote LTBI individuals showed signiﬁ-
cantly higher IFN-γ responses to Rv2628 antigen than recent LTBI sub-
jects, active TB and controls (Goletti et al., 2010). However, we studied
a very different population: 20% of QFT-GIT+ and 12% of QFT-GIT− sub-
jects were from other Latin American countries (Table 1), while the rest
were Argentinean. In addition, the genetic mixture of Argentinean peo-
ple is comprised by 79.9% European, 15.8% Native American, and 4.3%
African contributions, whichwould imply that therewas a fairly diverse
genetic background in the population studied (Corach et al., 2010;
Avena et al., 2006).
Since some HD subjects produced low levels of IFN-γ against
Rv2626c (Fig. 2), we searched for Rv2626c immunodominant epitopes
to which only LTBI individuals responded. None of the mentioned stud-
ies that tested latency antigens investigated the immunodominance of
peptide pools to discriminate LTBI individuals (Schuck et al., 2009;
Leyten et al., 2006; Chegou et al., 2012; Lin et al., 2007; Black et al.,
2009; Riano et al., 2012; Hozumi et al., 2013; Mensah et al., 2014;
Bashir et al., 2010; Goletti et al., 2010). We observed that pools C, B, D,
E and F all allowed improving the discernment between LTBI and HD
(Table 3), but pools B, D and F resulted the most speciﬁc and immuno-
genic ones. These ﬁndings reinforced our data showing that the re-
sponse to Rv2626c might allow discriminating between LTBI and HD.
Additionally, a signiﬁcantly higher cumulative IFN-γ response to the im-
munogenic peptide pools B, D and F was detected in LTBI individuals as
compared to HD (Table 3). Together, we demonstrated that speciﬁc im-
munogenic peptide pools from Rv2626cmight improve the discrimina-
tion of LTBI individuals from HD in a BCG-vaccinated population.
Interestingly, when we analyzed the response to Rv2626c both in
PBMCs and in whole blood from LTBI, HD and TB patients, we observed
that only LTBI individuals secreted signiﬁcant amounts of IFN-γ against
this antigen (Fig. 2A and B), indicating that the use of Rv2626c or its im-
munogenic peptides might comprise a new tool to differentiate LTBI in-
dividuals frombothHDandpatientswith active disease. Thus, the use of
Rv2626c in combinationwith ESAT-6 and CFP-10 could improve current
kits to allow the differential diagnosis of LTBI and active TB subjects.
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Fig. 2. IFN-γ production againstM. tuberculosis antigens in PBMCs andwhole blood fromnon-TB individuals and TB patients. (A) Peripheral bloodmononuclear cells (PBMCs) fromhealthy
donors (HD; N= 45), patients with tuberculosis (TB; N=56) and latentlyM. tuberculosis infected individuals (LTBI; N= 56) were culturedwith Rv2626c or CFP-10+ ESAT-6 for 5 days.
Then, cell free supernatants were recovered and IFN-γ production was evaluated by ELISA. (B) Whole blood from HD (N= 28), TB patients (N= 20) and LTBI individuals (N= 25) was
cultured with Rv2626c or CFP-10 + ESAT-6 for 24 h. Afterwards, plasma samples were collected and IFN-γ production was evaluated by ELISA. (A–B) Bars represent the Mean ± SEM.
Mann–Whitney test for unpaired samples. (C–D) ROC curve analyses for evaluation of the predictive value of whole blood IFN-γ levels produced in response to (C) Rv2626c or
(D) CFP-10+ ESAT-6, for differentiating (C) LTBI individuals from non-LTBI individuals (HD or TB), or (D) infected individuals (LTBI or active TB) from HD. Abbreviations: ROC, receiver
operating characteristic; AUC, area under the ROC curve.
889D. Peña et al. / EBioMedicine 2 (2015) 884–890Additionally, Rv2626c or its immunogenic peptide pools might be can-
didates to replace potential vaccine antigens present in current IGRAs.
In conclusion, the vast genetic mixture of Argentinean people makes
the use of Rv2626c or its immunogenic peptide pools promising to dis-
criminate individuals with active and latentM. tuberculosis infections in
BCG-vaccinated people. However, future studies should determine
whether Rv2626c might be also useful discriminating LTBI from TB
patients and healthy donors in non-BCG-vaccinated populations.
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